Krystal Biotech Inc. (KRYS)
142.06
-8.25 (-5.49%)
At close: Jan 14, 2025, 3:59 PM
142.64
0.41%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 114.2 |
| Market Cap | 4.09B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 1.77 |
| PE Ratio (ttm) | 80.26 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 180.53 |
| Volume | 345,818 |
| Avg. Volume (20D) | 256,090 |
| Open | 152.94 |
| Previous Close | 150.31 |
| Day's Range | 141.72 - 152.94 |
| 52-Week Range | 107.50 - 219.34 |
| Beta | undefined |
About KRYS
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive con...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 20, 2017
Employees 229
Stock Exchange NASDAQ
Ticker Symbol KRYS
Website https://www.krystalbio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for KRYS stock is "Buy." The 12-month stock price forecast is $212, which is an increase of 49.23% from the latest price.
Buy 85.71%
Hold 14.29%
Sell 0.00%
Next Earnings Release
Krystal Biotech Inc. is scheduled to release its earnings on Feb 24, 2025,
before market opens.
Analysts project revenue of $95.89M, reflecting a 127.53% YoY growth and earnings per share of 0.96, making a 220.00% increase YoY.
Analysts project revenue of $95.89M, reflecting a 127.53% YoY growth and earnings per share of 0.96, making a 220.00% increase YoY.
4 months ago ·
Source
+7.45%
Krystal Biotech shares are trading higher after St...
Unlock content with
Pro Subscription
8 months ago ·
Source
-2.58%
Krystal Biotech shares are trading lower after the company reported Q1 financial results.
